Incidencia de nefrotoxicidad por tenofovir en pacientes inmunodeprimidos por el virus de inmunodeficiencia humana en el Hospital de Infectología Dr. José Daniel Rodríguez Maridueña período 2015-2020
Fecha
2021
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Carrera de Medicina
Resumen
El tenofovir disoproxil fumarato es de primera línea en cualquier de los regímenes de tratamiento antirretroviral en paciente con VIH y se ha encontrado como uno de los principales factores para el desarrollo de la nefrotoxicidad. Objetivo: Calcular la Incidencia de Nefrotoxicidad por Tenofovir en pacientes inmunodeprimidos por el virus de Inmunodeficiencia Humana en el Hospital de Infectología Dr. José Daniel Rodríguez Maridueña en el periodo 2015-2020. Métodos: Cualitativo No experimental, descriptivo, Retrospectivo, de corte transversal, observación, teórico: Analítico. Resultados: incidencia con un 57% fue los pacientes con sexo masculino, y con 43% de sexo femenino, la mayor incidencia de edad es de 42% de 31 a 40 años, seguido de 26% de 41 a 50 años, 16% de 21-30 años, 14% de 51 a 60 años y 2% de 18 a 20 años. La incidencia del peso de los pacientes fue de 50% de 61 a 70 Kg, 26% de 51 a 60 kg, 13% de 71-80 kg, 11% de 40-50 kg. La incidencia de pacientes que presentaron comorbilidades fueron las siguientes, 54% tuvo hipertensión, 25% diabetes, 14% hepatitis b, 7% Ninguna comorbilidad. La incidencia del uso del tenofovir, 50% de 3 años, 29% con 2 años, 18% de un año, 3% de 6 meses, la gravedad de la disfunción renal se presentó en Moderada con 55%, severa con un 31% y leve con un 16%
Tenofovir disoproxil fumarate is first-line in any of the antiretroviral treatment regimens in patients with HIV and has been found to be one of the main factors for the development of nephrotoxicity. Objective: To calculate the Incidence of Nephrotoxicity by Tenofovir in patients immunosuppressed by the Human Immunodeficiency virus at the Hospital de Infectología Dr. José Daniel Rodríguez Maridueña in the period 2015-2020. Methods: Qualitative Non-experimental, descriptive, Retrospective, cross-sectional, observation. theoretical: Analytical. Results: incidence with 57% was male patients, and with 43% female. The highest incidence of age is 42% from 31 to 40 years, followed by 26% from 41 to 50 years, 16% of 21-30 years, 14% from 51 to 60 years and 2% from 18 to 20 years. The incidence of the weight of the patients was 50% from 61 to 70 kg, 26% from 51 to 60 kg, 13% from 71-80 kg, 11% from 40-50 kg. The incidence of patients who presented comorbidities were the following: 54% had hypertension, 25% diabetes, 14% hepatitis B, 7% No comorbidity. The incidence of tenofovir use, 50% at 3 years, 29% at 2 years, 18% at one year, 3% at 6 months, the severity of renal dysfunction was Moderate with 55%, severe with 31% and mild with 16%
Tenofovir disoproxil fumarate is first-line in any of the antiretroviral treatment regimens in patients with HIV and has been found to be one of the main factors for the development of nephrotoxicity. Objective: To calculate the Incidence of Nephrotoxicity by Tenofovir in patients immunosuppressed by the Human Immunodeficiency virus at the Hospital de Infectología Dr. José Daniel Rodríguez Maridueña in the period 2015-2020. Methods: Qualitative Non-experimental, descriptive, Retrospective, cross-sectional, observation. theoretical: Analytical. Results: incidence with 57% was male patients, and with 43% female. The highest incidence of age is 42% from 31 to 40 years, followed by 26% from 41 to 50 years, 16% of 21-30 years, 14% from 51 to 60 years and 2% from 18 to 20 years. The incidence of the weight of the patients was 50% from 61 to 70 kg, 26% from 51 to 60 kg, 13% from 71-80 kg, 11% from 40-50 kg. The incidence of patients who presented comorbidities were the following: 54% had hypertension, 25% diabetes, 14% hepatitis B, 7% No comorbidity. The incidence of tenofovir use, 50% at 3 years, 29% at 2 years, 18% at one year, 3% at 6 months, the severity of renal dysfunction was Moderate with 55%, severe with 31% and mild with 16%
Descripción
PDF
Palabras clave
NEFROTOXICIDAD, TENOFOVIR, VIRUS DE INMUNODEFICIENCIA HUMANA, INMUNODEPRIMIDOS, EPIDEMIOLOGIA DESCRIPTIVA, ESTUDIOS RETROSPECTIVOS, HOSPITAL DE INFECTOLOGIA DR. JOSE DANIEL RODRIGUEZ MARIDUEÑA, CANTON GUAYAQUIL, ECUADOR